CO2024016725A2 - Anticuerpo multiespecífico anti-taa/anti-cd3 - Google Patents

Anticuerpo multiespecífico anti-taa/anti-cd3

Info

Publication number
CO2024016725A2
CO2024016725A2 CONC2024/0016725A CO2024016725A CO2024016725A2 CO 2024016725 A2 CO2024016725 A2 CO 2024016725A2 CO 2024016725 A CO2024016725 A CO 2024016725A CO 2024016725 A2 CO2024016725 A2 CO 2024016725A2
Authority
CO
Colombia
Prior art keywords
taa
multispecific
antibody
scfv
various
Prior art date
Application number
CONC2024/0016725A
Other languages
English (en)
Spanish (es)
Inventor
Yoshiki Satake
Shigenori Yagi
Shinji Soga
Takashi Honda
Masahito Sato
Takashi Chaen
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CO2024016725A2 publication Critical patent/CO2024016725A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2024/0016725A 2022-05-12 2024-12-05 Anticuerpo multiespecífico anti-taa/anti-cd3 CO2024016725A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022078632 2022-05-12
PCT/JP2023/017663 WO2023219121A1 (ja) 2022-05-12 2023-05-11 抗ｔａａ－抗ｃｄ３多重特異性抗体

Publications (1)

Publication Number Publication Date
CO2024016725A2 true CO2024016725A2 (es) 2024-12-19

Family

ID=88730321

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0016725A CO2024016725A2 (es) 2022-05-12 2024-12-05 Anticuerpo multiespecífico anti-taa/anti-cd3

Country Status (11)

Country Link
US (1) US20250304706A1 (enExample)
EP (1) EP4524248A1 (enExample)
JP (1) JPWO2023219121A1 (enExample)
KR (1) KR20250010005A (enExample)
CN (1) CN119173633A (enExample)
AU (1) AU2023268258A1 (enExample)
CA (1) CA3256973A1 (enExample)
CO (1) CO2024016725A2 (enExample)
MX (1) MX2024013928A (enExample)
TW (2) TW202413430A (enExample)
WO (2) WO2023219120A1 (enExample)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686953U (enExample) 1979-12-08 1981-07-11
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU751659B2 (en) * 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
CN105722534B (zh) 2013-08-01 2019-05-31 艾更斯司股份有限公司 结合cd37蛋白的抗体药物偶联物(adc)
CN112390883A (zh) * 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR102669762B1 (ko) * 2016-12-19 2024-05-30 에프. 호프만-라 로슈 아게 표적화된 4-1bb(cd137) 작용물질과의 병용 요법
IL273217B2 (en) * 2017-09-22 2025-04-01 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
CR20230244A (es) 2020-11-16 2023-07-12 Astellas Pharma Inc Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
AR125398A1 (es) 2021-04-22 2023-07-12 Astellas Pharma Inc Anticuerpo biespecífico anti-cldn4 / anti-cd137

Also Published As

Publication number Publication date
CN119173633A (zh) 2024-12-20
MX2024013928A (es) 2024-12-06
CA3256973A1 (en) 2025-06-17
WO2023219121A1 (ja) 2023-11-16
AU2023268258A1 (en) 2024-11-28
WO2023219120A1 (ja) 2023-11-16
TW202413431A (zh) 2024-04-01
JPWO2023219121A1 (enExample) 2023-11-16
US20250304706A1 (en) 2025-10-02
EP4524248A1 (en) 2025-03-19
TW202413430A (zh) 2024-04-01
KR20250010005A (ko) 2025-01-20

Similar Documents

Publication Publication Date Title
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2023000499A1 (es) Proteínas que comprenden dominios de unión al antígeno de la hk2 y sus usos.
DOP2023000158A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
JOP20190116A1 (ar) الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
CY1122315T1 (el) Συνθεσεις αντισωματων για τη θεραπεια ογκων
PE20241349A1 (es) Anticuerpos de union a cd3
CO2019006500A2 (es) Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
CR20210225A (es) RECEPTORES DE ANTÍGENES QUIMÉRICOS BASADOS EN ANTICUERPOS DE DOMINIO SIMPLE Y MÉTODOS DE USO DE ESTOS (Divisional 2018-0153)
MX2024003355A (es) Anticuerpos anti-cd3.
CO2023018064A2 (es) Anticuerpos anti-ccr8 y usos de los mismos
AR063086A1 (es) Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
CO2023013511A2 (es) Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3
DOP2018000234A (es) Anticuerpos anti-basigin humanizados y uso de los mismos
EP4223778A4 (en) BISPECIFIC ANTIBODY TO CLAUDIN 18.2 AND CD3 AND ITS USE
EP4495142A3 (en) Bispecific antigen binding construct
MX2024002013A (es) Anticuerpos biespecificos anti-b7-h4/anti-4-1bb y usos de los mismos.
IL314678A (en) Bispecific antibodies against cd277 and a tumor-antigen
MX2023012995A (es) Anticuerpo biespecífico que se enlaza específicamente a cd47 y pd-l1.
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
CR20250226A (es) Anticuerpo anti-trem2 y usos del mismo
EP3672635A4 (en) Monoclonal antibodies against pathological alpha-synuclein, and methods using same